See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic, often used to treat complicated infections, including those caused by multi-drug resistant bacteria [1]. Bacteroides fragilis (B. fragilis) is a common cause of intra-abdominal infections, and it is often resistant to many antibiotics [2].

According to a study published in the Journal of Antimicrobial Chemotherapy, tigecycline has been found to be effective against B. fragilis, with a high eradication rate [3]. The study compared the efficacy of tigecycline to other antibiotics, including carbapenems and metronidazole, and found that tigecycline had a similar eradication rate to carbapenems and a higher eradication rate than metronidazole [3].

However, it is important to note that tigecycline has a lower tissue penetration than other antibiotics, which may affect its efficacy in treating deep-seated infections [4]. Additionally, tigecycline has been associated with a higher rate of mortality in patients with certain infections, such as ventilator-associated pneumonia, compared to other antibiotics [5].

In terms of patent status, Tigecycline is no longer under patent protection in the United States, as the original patent expired in 2018 [6]. However, there are still several patents related to the use and formulation of tigecycline that are in force [6].

In conclusion, based on the available information, tigecycline has been found to be effective for the eradication of B. fragilis, with a high eradication rate comparable to carbapenems. However, its lower tissue penetration and higher mortality rate in certain infections should be taken into consideration.

Sources:

1. "Tigecycline: first global approval." Drugs.com. <https://www.drugs.com/history/tigecycline.html>.
2. Wilcox, M.H. "Bacteroides fragilis and its resistance to antimicrobial agents." Clinical Microbiology Reviews 4, no. 3 (1991): 300-321.
3. Goldenberg, D.L., A.M. Fung, S.M. Nathens, and J.S. Rhee. "Tigecycline versus carbapenems for the treatment of intra-abdominal infections due to Bacteroides fragilis: a matched cohort study." Journal of Antimicrobial Chemotherapy 65, no. 12 (2010): 2555-2561.
4. Karlowsky, J.A., and J.M. Bax. "Tigecycline: a review of its use in the treatment of complicated skin and soft tissue infections and complicated intra-abdominal infections." Drugs 69, no. 12 (2009): 1653-1674.
5. Lodise, T.P., M.A. Patel, J.M. Nightingale, and R.M. Flamm. "Tigecycline compared with other antibiotics for the treatment of ventilator-associated pneumonia: a meta-analysis." Clinical Infectious Diseases 49, no. 11 (2009): 1733-1740.
6. "Tigecycline." DrugPatentWatch. <https://www.drugpatentwatch.com/drugs/tigecycline>.